Ipsen acquires Kartos Therapeutics in $1.75 billion deal
Ipsen agreed to acquire Kartos Therapeutics, a Redwood City, California-based clinical-stage biopharmaceutical company developing a treatment for myelofibrosis, a rare blood cancer, for $450 million upfront and up to $1.3 billion in additional milestone payments, bringing the total potential deal…



